A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies

Advances in biotechnology have enabled us to assay human tissue and cells to a depth and resolution that was never possible before, redefining what we know as the “biomarker”, and how we define a “disease”. This comes along with the shift of focus from a “one-drug-fits-all” to a “personalized approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Serelli-Lee, Victoria, Ito, Kazumi, Koibuchi, Akira, Tanigawa, Takahiko, Ueno, Takayo, Matsushima, Nobuko, Imai, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143954/
https://www.ncbi.nlm.nih.gov/pubmed/35629092
http://dx.doi.org/10.3390/jpm12050669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143954/
https://www.ncbi.nlm.nih.gov/pubmed/35629092
http://dx.doi.org/10.3390/jpm12050669

Ejemplares similares